Telix Pharmaceuticals (ASX:TLX) has reported a significant increase in its HY total group revenue, hitting A$220.8 million.

This figure is a nine-fold increase when compared to the first half of 2022, showing robust financial performance.

The company expresses an optimistic outlook for its product, Illuccix, in US and global markets, projecting an increase in adoption rates.

Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of molecularly targeted radiation (MTR) therapies for cancer treatment.